NCT03639324 - Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL | Biotech Hunter

Timeline

Start Date

October 2, 2020

Primary Completion Date

October 18, 2021

Study Completion Date

October 18, 2021

Conditions

Chronic Lymphocytic LeukemiaCLLRelapsed CLLRefractory Chronic Lymphocytic LeukemiaRelapsed Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaSLLRelapsed Small Lymphocytic LymphomaRefractory Small Lymphocytic Lymphoma

Interventions

DRUG

Dose combination 1-1

100 mg QD of idelalisib + 100 mg QD of venetoclax

DRUG

dose combination 1-2

100 mg QD of idelalisib + 200 mg QD of venetoclax

DRUG

Dose combination 1-3

100 mg BID of idelalisib + 200 mg QD of venetoclax

DRUG

dose combination 1-4

150 mg BID of idelalisib + 200 mg QD of venetoclax

DRUG

Sub-Trial: Dose combination 2-1

100 mg BID of idelalisib + 100 mg QD of venetoclax

DRUG

Sub-Trial: Dose combination 2-2

150 mg BID of idelalisib + 100 mg QD of venetoclax